Filana Therapeutics (FLNA) risk factors

Item 1A of every Filana Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open FLNA in Gloom →

Filana Therapeutics' chart, financials and news, free in your browser.Open FLNA in Gloom →

FY2025 10-K risk factors
99 risks10 new11 dropped16 reworded
Filana Therapeutics shifted its primary focus from Alzheimer's disease to TSC-related epilepsy in mid-2025, following the failure of its Phase 3 Alzheimer's trials.
Filed Mar 12, 2026
FY2024 10-K risk factors
100 risks
Filana Therapeutics faces intense risk centered on the clinical development and regulatory approval of its lead drug, simufilam, targeting Alzheimer’s disease and epilepsy.
Filed Mar 03, 2025